## **Core Concept**
Leukotriene receptor antagonists (LTRAs) are a class of drugs used in the management of bronchial asthma. They work by blocking the action of leukotrienes, which are inflammatory mediators involved in the pathogenesis of asthma. Leukotrienes cause bronchoconstriction, increase mucus production, and attract inflammatory cells.

## **Why the Correct Answer is Right**
Montelukast is a specific leukotriene receptor antagonist that blocks the cysteinyl leukotriene receptor (CysLT1 receptor). By blocking this receptor, montelukast prevents the bronchoconstrictive and pro-inflammatory effects of leukotrienes, thereby reducing inflammation, airway edema, and smooth muscle contraction. This mechanism makes montelukast effective in controlling symptoms of asthma and preventing exacerbations.

## **Why Each Wrong Option is Incorrect**
- **Option A:** Zafirlukast is also a leukotriene receptor antagonist but is not the correct answer provided.
- **Option B:** Zileuton is a leukotriene synthesis inhibitor, not a receptor antagonist. It works by inhibiting the enzyme 5-lipoxygenase, which is involved in the production of leukotrienes.
- **Option D:** Prednisolone is a corticosteroid, not a leukotriene receptor antagonist. Corticosteroids are anti-inflammatory drugs used in asthma but work through a different mechanism.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that leukotriene modifiers, including montelukast, are particularly useful in patients with mild to moderate asthma who have inadequate control with inhaled corticosteroids alone or as add-on therapy. They are also beneficial for patients with aspirin-exacerbated respiratory disease (AERD).

## **Correct Answer:** . Montelukast